How would you approach second line treatment for prostate adenocarcinoma with diffuse neuroendocrine features?
What would you use after platinum/taxane/IO first line therapy?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on
Men with NEPC (histologic evidence of small cell carcinoma) face a poor prognosis and are typically refractory to all hormonal interventions, and in fact transformed NEPC much more typically evolves after potent AR inhibition than present de novo at diagnosis. Autopsy series and biopsy series sugges...
Join for free or sign in to see the full answer